| Outside Days Offer Intriguing Options Opportunity |
Last week, I took a closer look at outside days on a candlestick chart of the S&P 500 Index (SPX). |
schaeffersresearch.com |
2025-05-14 12:00:10 |
Czytaj oryginał (ang.) |
| Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet |
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach. |
seekingalpha.com |
2025-05-12 16:30:03 |
Czytaj oryginał (ang.) |
| Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal |
Paris, May 12 , 2025 - Jeito Capital (“Jeito”), a global leading independent Private Equity fund dedicated to biopharma, is pleased to announce the promotion of Mehdi Ainouche to Partner and Julien Elric to Senior Principal. |
globenewswire.com |
2025-05-12 05:00:00 |
Czytaj oryginał (ang.) |
| BIIB's Q1 Earnings Miss, Revenues Top Mark, 2025 EPS Guidance Cut |
Biogen reports mixed first-quarter 2025 results. It also lowers its EPS guidance for the current year. |
zacks.com |
2025-05-01 17:45:41 |
Czytaj oryginał (ang.) |
| Biogen Inc. (BIIB) Q1 2025 Earnings Call Transcript |
Biogen Inc. (NASDAQ:BIIB ) Q1 2025 Earnings Conference Call May 1, 2025 8:30 AM ET Company Participants Tim Power - Head, Investor Relations Chris Viehbacher - President & Chief Executive Officer Priya Singhal - Head, Development Robin Kramer - Chief Financial Officer Conference Call Participants Brian Abrahams - RBC Capital Markets Evan Seigerman - BMO Capital Markets Salveen Richter - Goldman Sachs Tim Anderson - Bank of America Chris Schott - JPMorgan Michael Yee - Jefferies Mike DiFiore - Evercore ISI Terence Flynn - Morgan Stanley Geoff Meacham - Citibank Operator Good morning. My name is Melinda, and I'll be your conference operator today. |
seekingalpha.com |
2025-05-01 15:38:23 |
Czytaj oryginał (ang.) |
| Biogen (BIIB) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates |
Although the revenue and EPS for Biogen (BIIB) give a sense of how its business performed in the quarter ended March 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers. |
zacks.com |
2025-05-01 14:36:24 |
Czytaj oryginał (ang.) |
| Biogen Inc. (BIIB) Q1 Earnings Lag Estimates |
Biogen Inc. (BIIB) came out with quarterly earnings of $3.02 per share, missing the Zacks Consensus Estimate of $3.26 per share. This compares to earnings of $3.67 per share a year ago. |
zacks.com |
2025-05-01 13:05:42 |
Czytaj oryginał (ang.) |
| Biogen beats quarterly profit estimates on strong demand for rare disease drugs |
Biogen beat first-quarter profit and revenue expectations on Thursday, as strong demand for its rare disease drugs helped offset declining sales of its multiple sclerosis drugs. |
reuters.com |
2025-05-01 10:48:55 |
Czytaj oryginał (ang.) |
| Unveiling Biogen (BIIB) Q1 Outlook: Wall Street Estimates for Key Metrics |
Get a deeper insight into the potential performance of Biogen (BIIB) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics. |
zacks.com |
2025-04-30 14:21:02 |
Czytaj oryginał (ang.) |
| Will These 5 Big Drug Stocks Surpass Q1 Earnings Forecasts? |
Let's look at five pharma and drug companies, PFE, LLY, AMGN, BIIB and REGN, which are scheduled to release their first-quarter 2025 results later this week. |
zacks.com |
2025-04-28 17:11:16 |
Czytaj oryginał (ang.) |
| Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? |
Biogen: Is This A Value Trap, Or Is The Great Turnaround Imminent? |
seekingalpha.com |
2025-04-25 13:15:51 |
Czytaj oryginał (ang.) |
| Earnings Preview: Biogen Inc. (BIIB) Q1 Earnings Expected to Decline |
Biogen (BIIB) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations. |
zacks.com |
2025-04-24 15:09:04 |
Czytaj oryginał (ang.) |
| Can Biogen Keep the Beat Streak Alive This Earnings Season? |
In the first quarter, lower sales of BIIB's multiple sclerosis drugs are likely to have been offset by revenues from new drugs. |
zacks.com |
2025-04-24 11:55:33 |
Czytaj oryginał (ang.) |
| Biogen & Partner Eisai Get EU Nod for Alzheimer's Drug Leqembi |
Following the nod in the EU, BIIB & Eisai's Leqembi becomes the first therapy to slow the progression of early Alzheimer's disease in the region. |
zacks.com |
2025-04-16 16:50:35 |
Czytaj oryginał (ang.) |
| Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (early AD) who are apolipoprotein E ε4 (ApoE ε4 * ) non-carriers or heterozygotes with confirmed amyloid pathology |
globenewswire.com |
2025-04-15 23:00:00 |
Czytaj oryginał (ang.) |
| EU authorizes Eisai-Biogen's drug for treatment of early Alzheimer's disease |
The European Commission on Tuesday authorized the use of Eisai and Biogen's drug to treat mild cognitive impairment in the early stages of Alzheimer's disease. |
reuters.com |
2025-04-15 15:47:21 |
Czytaj oryginał (ang.) |
| Biogen (BIIB) Soars 5.7%: Is Further Upside Left in the Stock? |
Biogen (BIIB) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
zacks.com |
2025-04-10 14:55:37 |
Czytaj oryginał (ang.) |
| Sage Therapeutics: Biogen's $7.22/Share Bid Might Say More Than The Price Tag |
Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals confidence in Sage's commercial potential and drug pipeline, despite the market's current undervaluation. Sage's Zuranolone shows strong market traction in PPD, with significant insurance coverage and increasing prescriptions, indicating future growth potential. |
seekingalpha.com |
2025-04-09 09:34:38 |
Czytaj oryginał (ang.) |
| BIIB's Experimental Alzheimer's Drug Gets FDA Fast Track Tag |
The FDA's fast track designation will facilitate rapid development and expedited review of Biogen's Alzheimer's disease candidate. |
zacks.com |
2025-04-03 15:50:38 |
Czytaj oryginał (ang.) |
| Biogen's Investigational Tau-Targeting Therapy BIIB080 Receives FDA Fast Track Designation for the Treatment of Alzheimer's Disease |
CAMBRIDGE, Mass., April 02, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to BIIB080, an investigational antisense oligonucleotide (ASO) therapy targeting tau, for the treatment of Alzheimer's disease. Fast Track designation is intended to facilitate the development and expedite the review of investigational drugs that treat serious conditions and address unmet medical needs. |
globenewswire.com |
2025-04-02 11:30:00 |
Czytaj oryginał (ang.) |
| These Were the 5 Worst-Performing Stocks in the Nasdaq-100 in 2024 |
Now that we've shut the door on 2024, it's useful to look back at some of the best -- and, on the flip side, some of the worst -- performers of the year on the stock market. Many outliers were in the tech sector, so it's worth taking a look at the tech-heavy Nasdaq-100 index. |
fool.com |
2025-01-04 09:45:00 |
Czytaj oryginał (ang.) |
| Why Biogen Inc. (BIIB) is a Top Value Stock for the Long-Term |
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage. |
zacks.com |
2025-01-01 12:51:39 |
Czytaj oryginał (ang.) |
| Beaten Down Biogen Stock Looks Attractive At Current Levels |
The Biogen Inc. story of the last 10 years has been one of periods of excitement, followed by significant disappointments. The company is executing a turnaround strategy that includes cost-cutting, pipeline realignment, and M&A. Leqembi's launch is below expectations, but is improving lately, with good sequential growth trends in Q3. |
seekingalpha.com |
2024-12-30 15:37:47 |
Czytaj oryginał (ang.) |
| Pharma has value names, but it's not a top pick for 2025, says BMO's Evan Siegerman |
Evan Siegerman, BMO biotech analyst, joins 'Power Lunch' to discuss the big winners in the pharmaceutical space in 2025. |
youtube.com |
2024-12-23 17:45:24 |
Czytaj oryginał (ang.) |
| Private Medicare plans must cover Biogen's ALS drug, US agency says |
The Centers for Medicare & Medicaid Services has directed private insurers providing Medicare Advantage plans to cover Biogen's amyotrophic lateral sclerosis drug Qalsody after finding instances of coverage denial. |
reuters.com |
2024-12-12 14:52:10 |
Czytaj oryginał (ang.) |
| Analysts Predict These Will Be Next Year's Top 10 Stocks |
Missed out on this year's top S&P 500 stocks? Analysts are already offering up their ideas on which stocks will rule in 2025. |
investors.com |
2024-12-11 10:00:52 |
Czytaj oryginał (ang.) |
| Biogen Stock Declines 21.4% in 3 Months: How to Play the Stock |
Though there is uncertainty about Biogen's sales and profits improving significantly, investors can hold the stock given the potential of its new drugs. |
zacks.com |
2024-12-10 11:35:25 |
Czytaj oryginał (ang.) |
| Biogen Downgraded On Pipeline Setbacks And Leqembi Sales Slowdown |
Jefferies downgraded Biogen Inc BIIB, citing the company's tough setup. |
benzinga.com |
2024-12-09 15:44:13 |
Czytaj oryginał (ang.) |
| Biogen Inc. (BIIB) Presents at 7th Annual Evercore ISI HealthCONx Healthcare Conference Call Transcript |
Biogen Inc. (NASDAQ:BIIB ) 7th Annual Evercore ISI HealthCONx Healthcare Conference Call December 3, 2024 9:10 AM ET Company Participants Alisha Alaimo - President and Head of North America Michael McDonnell - Chief Financial Officer Conference Call Participants Umer Raffat - Evercore ISI Umer Raffat Okay, thank you guys for joining us. Pleasure to have Biogen Management. |
seekingalpha.com |
2024-12-03 14:15:29 |
Czytaj oryginał (ang.) |
| Biogen expects steady growth for Alzheimer's drug Leqembi in near term |
Biogen expects growth of its keenly watched Alzheimer's disease drug, Leqembi, to see a "linear trend" in the United States in the near term, a company executive said at a healthcare conference on Tuesday. |
reuters.com |
2024-12-03 11:57:42 |
Czytaj oryginał (ang.) |
| These Are the 5 Worst-Performing Stocks in the Nasdaq-100 With 2024 Almost Over |
The Nasdaq-100 index tracks the largest 100 non-financial companies on the Nasdaq stock exchange. Although it's not a part of the U.S. stock market's big three indexes ( S&P 500 , Nasdaq Composite, and Dow Jones), the Nasdaq-100 has grown in popularity over the years because of its concentration of tech stocks (almost 60%), many of which have seen their valuations skyrocket in recent years. |
fool.com |
2024-11-26 09:30:00 |
Czytaj oryginał (ang.) |
| Biogen Gains Momentum With Positive Lupus Drug Results, Analyst Sees Modest Valuation Upside |
On Tuesday, UCB SA UCBJY UCBJF and Biogen Inc. BIIB presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP) for systemic lupus erythematosus. |
benzinga.com |
2024-11-20 15:32:29 |
Czytaj oryginał (ang.) |
| Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity |
BRUSSELS, Belgium and CAMBRIDGE, Mass., Nov. 19, 2024 (GLOBE NEWSWIRE) -- UCB (Euronext Brussels: UCB) and Biogen Inc. (NASDAQ: BIIB) today presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug candidate, demonstrating significant clinical improvement in disease activity in people living with moderate-to-severe systemic lupus erythematosus (SLE). The results were shared during an oral, late-breaker presentation at ACR Convergence 2024, the American College of Rheumatology's annual meeting, in Washington, DC. |
globenewswire.com |
2024-11-19 03:00:00 |
Czytaj oryginał (ang.) |
| Biogen's Outlook Dims As Analyst Projects Flat Revenue Until 2026 |
Needham downgraded Biogen Inc BIIB, citing limited catalysts for the company over the next year. |
benzinga.com |
2024-11-18 15:18:42 |
Czytaj oryginał (ang.) |
| Samsung Bioepis and Biogen Receive European Commission (EC) Approval for Aflibercept Biosimilar, OPUVIZ™ |
INCHEON, South Korea and CAMBRIDGE, Mass., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Samsung Bioepis Co., Ltd. and Biogen Inc. (Nasdaq: BIIB) today announced that the European Commission (EC) has approved OPUVIZ™ 40 mg/mL solution for injection in a vial, a biosimilar referencing Eylea1,2 (aflibercept), developed and registered by Samsung Bioepis. |
globenewswire.com |
2024-11-18 09:00:00 |
Czytaj oryginał (ang.) |
| Biogen Partner Eisai Gets Positive CHMP Nod for Leqembi in Europe |
The CHMP renders a positive opinion recommending approval for BIIB and Eisai's Leqembi for treating early Alzheimer's disease. |
zacks.com |
2024-11-15 12:05:15 |
Czytaj oryginał (ang.) |
| Biogen's stock rises after E.U. regulator reverses negative view of Alzheimer's drug |
Biogen's stock rose 1% Thursday, after Europe's pharmaceutical regulator issued a positive opinion on the Alzheimer's disease drug that the company developed with Japanese partner Eisai — reversing an earlier decision not to approve the drug. |
marketwatch.com |
2024-11-14 15:21:00 |
Czytaj oryginał (ang.) |
| Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer's Disease |
TOKYO and CAMBRIDGE, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced today a positive opinion has been received from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) recommending approval of the amyloid-beta (Aβ) monoclonal antibody lecanemab as a treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer's disease (Early Alzheimer's disease) who are apolipoprotein E ε4 (ApoE ε4)* non-carriers or heterozygotes with confirmed amyloid pathology.1 Eisai had requested a re-examination of the prior negative opinion adopted by the CHMP in July 2024. In accordance with European Medicines Agency regulatory process, the European Commission is expected to make a final decision on the marketing authorization application (MAA) of lecanemab based on the CHMP recommendation within 67 days of receipt of CHMP opinion.2 |
globenewswire.com |
2024-11-14 13:23:00 |
Czytaj oryginał (ang.) |
| EU drugs regulator recommends Alzheimer's drug from Eisai-Biogen |
The European Union's drugs regulator on Thursday said it recommends approval of Eisai and Biogen's Leqembi in patients with early Alzheimer's disease, months after the agency first rejected the treatment. |
reuters.com |
2024-11-14 13:17:28 |
Czytaj oryginał (ang.) |
| Biogen initiated with a Neutral at Citi |
Citi analyst Geoff Meacham initiated coverage of Biogen with a Neutral rating and $190 price target. The company's strategy to offset core franchise erosion has been to develop assets with significant unmet need in very difficult indications, the analyst tells investors in a research note. The firm says Biogen's pipeline still looks to have higher clinical risk overall versus the company's big biotech peers, "but this also conveys significant option value." |
https://thefly.com |
2024-11-13 18:13:22 |
Czytaj oryginał (ang.) |